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Introduction: Regulatory reliance, harmonization and work sharing have grown over
the last few years, resulting in greater sharing of work and information among regulators,
enabling efficient use of limited resources and preventing duplication of work. Various
initiatives on the African continent include ZaZiBoNa, the Southern African Development
Community (SADC) collaborative medicines registration initiative. ZaZiBoNa has resulted
in great savings in time and resources; however, identified challenges include lack of clear
information regarding the participating countries registration processes and requirements
as well as lengthy registration times. The aim of this study, therefore, was to compare
the data requirements and review models employed in the assessment of applications
for registration, the target timelines for key milestones and the metrics of applications
received and approved in 2019 and 2020 by Mozambique, Namibia, South Africa,
Tanzania, Zambia, and Zimbabwe.
Methods: A senior member of the division responsible for issuing marketing
authorisations completed an established and validated questionnaire, which
standardizes the review process, allowing key milestones, activities and practices
of the six regulatory authorities to be identified and compared. The completed
questionnaires were validated by the heads of the respective agencies.
Results: The majority of applications received and approved by all six agencies in 2019
and 2020 were for generics. The mean approval times for generics varied across the
countries, with ranges of 218–890 calendar days in 2019 and 158–696 calendar days
in 2020. All three types of scientific assessment review models were used by the six
agencies and data requirements and extent of scientific assessment were similar for five
countries, while one conducted full reviews for new active substances. A large variation
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was observed in the targets set by the six agencies for the different milestones as well
as overall approval times.
Conclusions: The study identified the strengths of the countries as well as opportunities
for improvement and alignment. Implementation of the recommendations made as in this
study will enhance the countries’ individual systems, enabling them to efficiently support
the ZaZiBoNa initiative.
Keywords: South African Development Community, ZaZiBoNa, regulatory reliance, regulatory review models,
regulatory approval timelines
INTRODUCTION
Medicine regulation contributes to public health by ensuring
timely access to medicines that have been reviewed and
found to be safe, effective, and of good quality. Regulation
of medicines has evolved from the publishing of minimum
standards for compliance to the development of legislation
controlling the development, manufacture, distribution, sale, and
use of medicines (1). One function, performed by regulatory
authorities worldwide to fulfill their mandate, is the process of
reviewing applications for registration or market authorization
submitted by companies interested in marketing their products
in a particular country or jurisdiction. This process can be long
in some countries, hindering access to life-saving medicines by
patients and this has led to regulatory agencies relying on the
reviews and decisions of other regulators (2).
Reliance
It is now acknowledged that no one regulator can do everything
for themselves due to increasing workload and complexity of
products (3) and this is especially true for maturing agencies in
low- -to-middle-income countries (LMICs) who often do not
have adequate resources or capacity to perform full regulatory
functions. Reliance on work done by other agencies drastically
reduces the time to market for medicines, resulting in improved
patient access (4, 5). The World Health Organization (WHO)
has now published its guidance on good reliance practices
(3) and recommends the use of reliance to effectively and
efficiently perform regulatory functions in a timely and cost-
effective manner.
Registering Medicines in LMICs:
Challenges
Applicants submitting applications for registration of medicines
to LMICs have often cited the challenges of lack of clear
information on the registration process and timelines,
inefficiencies in the registration process, lack of harmonization
of requirements for countries in one region and long registration
timelines (6, 7). On the other hand, applicants also contribute
to the delay in the approval process by taking too long to
respond to queries raised by regulators (8). There is therefore
need for an evaluation of the regulatory review processes and
registration timelines of agencies in LMICs to address the
challenges identified and fill the knowledge gap. In the first
paper of this two part-series, we evaluated and compared the
regulatory review processes of the regulatory authorities of
Mozambique, Namibia, South Africa, Tanzania, Zambia, and
Zimbabwe, who are active members of the ZaZiBoNa initiative
and proposed recommendations for better alignment The aim
of this paper, the second and last in the series, was to compare
the data requirements and review models employed in the
assessment of applications for registration, the target timelines
for key milestones and the metrics of applications received and
approved in 2019 and 2020 by the six countries.
MATERIALS AND METHODS
Study Participants
Nine countries with active member status in the ZaZiBoNa
initiative were invited to participate in the study following a face-
to-face presentation. Active member status is defined as “the
capacity to conduct assessments and GMP inspections.” One of
the countries (Botswana) could not complete the questionnaire
because their agency had only recently been established and
the lack of participation by two countries (the Democratic
Republic of Congo andMalawi) was likely because of disruptions
caused by the Covid-19 pandemic. Therefore, the six regulatory
agencies included in this study were the National Directorate
of Pharmacy in the Mozambique Ministry of Health; Namibia
Medicines Regulatory Council (NMRC) in the Namibia Ministry
of Health and Social Services; the South African Health Products
Regulatory Authority (SAHPRA); the Tanzania Medicines and
Medical Devices Authority (TMDA); the Zambian Medicines
Regulatory Authority (ZAMRA); and the Medicines Control
Authority of Zimbabwe (MCAZ).
Data Collection
Each of the six agencies completed an established and validated
questionnaire (9) in 2020, which described the organizational
structure, the regulatory review system for market authorization
for new active substances (NASs) and generics as well as their
overall target and review times from the date of application to
the date of approval, good review practices (GRevPs) and quality
decision-making practices. The questionnaire allowed for the
collection of data in a standardized format, enabling comparison,
and analyses of information collected from the six agencies.
The questionnaire consists of five parts: Part 1, documents
the structure, organization and resources of the agency; Part 2,
identifies different types of review model(s) used for the scientific
assessment of medicines; Part 3, documents information on
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the key milestone dates and the process using a standardized
process map; Part 4, records how overall quality is built into the
regulatory process (GrevPs) and Part 5, explores the quality of the
decision-making practices of the agency.
Models of Regulatory Review
There are three models for the scientific regulatory review of a
product that can be used by regulatory authorities (9):
• The verification review (type 1), which requires prior
approval of a product by two or more reference or competent
regulatory authorities, allowing the agency relying on such
assessments to employ a verification process to validate
a product and ensure that it conforms to the previously
authorized product specifications. This should also conform
with the prescribing information such as the use, dosage
and precautions.
• The abridged review (type 2), which involves an abridged
evaluation of a medicine, taking into consideration local
factors and the environment as well as a benefit-risk
assessment in relation to its use in the local ethnic population
including medical practice and pattern of disease. This further
requires registration by at least one reference or competent
regulatory authority.
• The full review, type 3A, which involves the agency carrying
out a full review, including supporting scientific data, of
quality, safety and efficacy, but requires that the product be
previously reviewed by an agency and issued a Certificate of
Pharmaceutical Product (CPP) or type 3B, which involves
an independent assessment of a product’s quality, preclinical
and clinical safety and efficacy, which has not previously been
evaluated by any other agency.
Ethics Committee Approval
The study was approved by the Health, Science,
Engineering and Technology ECDA, University of
Hertfordshire, United Kingdom [Reference Protocol number:
LMS/PGR/UH/04350].
RESULTS
For the purpose of clarity, the results will be presented in three
parts: Part I—metrics of applications received and registered;
Part II—review models, extent of scientific assessment and data
requirements; and Part III—targets of key milestones in the
review process.
Part I—Metrics on NASs, Generics, and
WHO-Prequalified Generics
Applications Received and Approved
The majority of applications received and approved by all
six agencies in 2019 and 2020 were for generics. In 2019
Mozambique and Zambia did not receive any applications for
new active substances (NASs), while Tanzania only received 1,
with Namibia, South Africa and Zimbabwe receiving 14, 11, and
8, respectively (Table 1). Tanzania received the highest number
of generic applications (858) and Namibia received the lowest
(132). Interestingly, even though Zambia and Zimbabwe are
comparable in population size and fees payable, Zambia received
close to three times the number of generic applications compared
with Zimbabwe and this might be attributed to differences
in their economies and perceived return on investment by
applicants (Figure 1). The year 2020 saw a decline in applications
for NASs received by the agencies, with the exception of South
Africa, which saw an increase. Tanzania, Zambia, and Zimbabwe
saw a decrease in generics in 2020, while Mozambique, Namibia
and South Africa saw an increase (Table 1). Namibia and
Tanzania saw a decrease in WHO-prequalified generics in 2020
while Mozambique, Zambia, and Zimbabwe saw an increase.
Mean Approval Times
For NASs, South Africa had the longest average approval time
of all the agencies (Table 2) as they are the only country that
conducts a full review of NASs. Namibia had an approval
time of 170 days while Zimbabwe had an approval time
of 219 days and these were assessed using abridged review
(Table 2). Mozambique, Tanzania and Zambia did not approve
any NASs in the 2 years. For generics, Tanzania had the shortest
approval time even though they received the highest number
of applications. Tanzania’s approval times for generics were
comparable to Zambia’s times. The longest approval time for
generics was observed for Namibia in 2019 however the time
was significantly reduced in 2020. South Africa and Zimbabwe’s
approval times for generics were comparable (Figure 2). South
Africa is implementing reliance in their backlog programme
resulting in much shorter review times than those reported for
business as usual.
Part II—Review Models Used for Scientific
Assessment
In general, all three types of review models are used for scientific
assessment by the six agencies (Table 3).
Verification Review (Type 1)
Five agencies apart from Tanzania conducted verification reviews
with the requirement for the product to have been approved
by at least one reference agency, while South Africa required
approval by two reference agencies. Unredacted reports were
required to facilitate a verification review. However, because
of a lack of agreements with other WHO-listed regulatory
authorities, Mozambique and Zimbabwe only recognized WHO
prequalification (WHO PQ) and the ZaZiBoNa collaborative
procedure as reference agencies for this pathway. In addition
to products approved by WHO Prequalification and ZaZiBoNa,
Namibia, South Africa, and Zambia conducted verification
reviews of products approved by WHO-listed regulatory
authorities; however, only South Africa and Zambia had
agreements to access the unredacted reports from these
reference agencies. Namibia also recognized South Africa and
Zimbabwe as reference agencies. The reference agencies common
to all countries were the WHO PQ, European Medicines
Agency (EMA), Medicines and Healthcare Products Regulatory
Authority (MHRA), United States Food Drug Administration
(USFDA), Australia’s Therapeutic Goods Administration (TGA),
Frontiers in Medicine | www.frontiersin.org 3 August 2021 | Volume 8 | Article 742200
Sithole et al. SADC Review Models and Approval Timelines
TABLE 1 | Comparison of metrics on NASs, generics, and WHO prequalified generics (2019–2020).
Country Mozambique Namibia South Africa Tanzania Zambia Zimbabwe
Year 2019 2020 2019 2020 2019a 2020b 2019 2020 2019 2020 2019 2020
NASs
Received 0 0 14 0 11 57 1 0 0 0 8 4
Approved 0 0 14 0 43 97 1 0 9 1 4 0
Generics
Received 198 339 132 227 29 331 858 631 574 206 195 179
Approved 291 278 70 46 156 165 591 499 454 217 122 107
WHO-prequalified generics
Received 10 15 8 4 0 N/A 14 7 11 28 5 9
Approved 8 9 8 1 0 0 14 7 11 28 7 7
NASs, new active substances; WHO, World Health Organization; N/A, Not available.
aData is for August to December due to closure of the agency for part of the year.
bData for business as usual only. Excludes backlog.
FIGURE 1 | Comparison of number of generics approved in 2019 and 2020.
TABLE 2 | Comparison of mean approval times of NASs, generics and WHO prequalified generics 2019–2020 (calendar days).
Country Mozambique Namibia South Africa Tanzania Zambia Zimbabwe
Year 2019 2020 2019 2020 2019a 2020b 2019 2020 2019 2020 2019 2020
NASs 0 0 170 0 490 585 0 0 0 0 219 0
Generics 310 398 890 158 589 683 218 202 240 214 611 696
WHO PQ generics 100 118 120 131 0 298 78 83 45 53 150 137
aData is for August to December due to closure of the agency for part of the year.
bData for business as usual only. Excludes backlog.
Health Canada, Japan’s Pharmaceuticals and Medical Devices
Agency (PMDA), and other mature agencies (WHO listed
authorities) in Europe. Mozambique, South Africa, Zambia,
and Zimbabwe had a target time of 90 calendar days for
verification review, while the target was 270 calendar days
for Namibia.
Abridged Review (Type 2)
Five agencies except Zambia conducted an abridged review for
products approved by at least one reference agency. For this type
of review, redacted or public assessment reports were used and
differences in medical culture/practice, ethnic factors, national
disease pattern and unmet medical needs were taken into
account during benefit-risk assessment. These considerations
were also made during a verification review. For Zambia, an
abridged reviewwas conducted for established products that were
considered to be of low risk. South Africa had a target time
of 90 calendar days, Tanzania 126 calendar days, Mozambique,
Namibia, and Zimbabwe 270 calendar days and Zambia 351
calendar days.
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FIGURE 2 | Comparison of mean approval times for generics in 2019 and 2020.
TABLE 3 | Review models employed and target timelines (calendar days).


















Verification review (type 1) Xa Xb# Xb* ✘ Xc Xa
Target 90 270 90 N/A 90 90
Abridged review (type 2) Xb Xc# Xb Xc Xd Xb
Target 270 270 90 126 351 270
Full review (type 3) X X X X X X
Target 365 No target 350 252 351 480
Fast Track / Priority Review X X X X X X
Target >180 90 250 126 113 180
aFor WHO collaborative registration procedure (CRP) and ZaZiBoNa-recommended products.
bFor WHO CRP, stringent regulatory authority (SRA)-approved and ZaZiBoNa-recommended products.
cFor WHO-prequalified and SRA-approved products.
dFor legacy molecules with minimal risk.
# Includes Zimbabwe and South Africa.
*Must be approved by two reference agencies.
Full Review (Type 3)
All six agencies conducted a full review (type 3) of quality, safety,
and efficacy for all major applications that were not eligible
for verification or abridged review (Table 4). For Mozambique
and Namibia, this comprised an extensive assessment of the
chemistry, manufacturing and control (CMC) data for all
product types as well as the bioequivalence for generics as all
new chemical entities received had already been approved by
a reference agency. For South Africa, Tanzania, and Zambia,
this involved a full review of the CMC for all product types,
bioequivalence for generics, and non-clinical and clinical data
for new chemical entities, biologicals and biosimilars inclusive of
those that had not been approved anywhere else. For Zimbabwe,
this involved an extensive assessment of the CMC for all product
types, bioequivalence for generics and the non-clinical and
clinical data for biosimilars only as all new chemical entities
received had already been approved by a reference agency
(Table 4). In five agencies the quality, safety and efficacy sections
were reviewed sequentially whereas South Africa conducted
all reviews in parallel. Zimbabwe reviewed the majority of
applications sequentially, although biosimilars were reviewed in
parallel. Namibia had no target time for the overall approval
of a full review. The target for Mozambique was 365 days
excluding applicant’s time and this is comparable to the target
times for the comparator countries: South Africa 350 days
excluding the applicant time; Tanzania 252 days excluding
applicant time; Zambia 351 days inclusive of the applicant
time; and Zimbabwe 480 days inclusive of the applicant time
(Table 3). These targets are further broken down into individual
milestones in Table 6.
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TABLE 4 | Extent of scientific assessment for full review.
Mozambique Namibia South Africa Tanzania Zambia Zimbabwe
Chemistry, manufacturing and control (CMC) data extensive assessment X X X X X X
Non-clinical data extensive assessment ✘ ✘ X X X Xa
Clinical data extensive assessment ✘ ✘ X X X Xa
Bioequivalence data extensive assessment ✘ X X X X X
Additional information obtained (where appropriate)
Other agencies internal review reports X X X X X X
Medical and scientific literature X X X X X X
aFor biosimilar products not approved by a reference agency only.
TABLE 5 | Summary comparison of key features of the regulatory systems for medicines.
Marketing authorisations Mozambique Namibia South Africa Tanzania Zambia Zimbabwe
Certificate of a Pharmaceutical Product (CPP): CPP is required with the application or
before authorization is issued
X ✘ X Xa X X
Common technical document (CTD): CTD format is mandatory for applications X X X X X X
Medical staff: More than 25% within the agency review staff are physicians ✘ ✘ ✘ ✘ ✘ ✘
Review times: The agency sets targets for the time it spends on the scientific
assessment of NASs and generic applications
X ✘ X X X X
Approval times: The agency has a target for the overall time for the review and
approval of an application
X ✘ X X X X
Questions to sponsors are batched at fixed points in the review procedure X X X X X X
Company response time: Recording procedures allow the company response time to
be measured and differentiated in the overall processing time
X X ✘ X X X
Priority reviews: The agency recognizes medical urgency as a criterion for
accelerating the review and approval process for qualifying products
X X X X X X
Sequential processing: Different sections of technical data reviewed sequentially
rather than in parallel
X X ✘ X X Xb
Price negotiation: Discussion of pricing is separate from the technical review and
does not delay the approval of products
X X X X X X
Sample analysis: The focus is on checking quality in the marketplace and
requirements for analytical work do not delay the marketing authorization
X X X X X X
aFor abridged review (type 2) only.
bBiosimilars reviewed in parallel.
Fast-Track/Priority Review
The target for priority review was 90 calendar days for Namibia,
113 calendar days for Zambia, 126 calendar days for Tanzania,
180 calendar days for Zimbabwe, 250 calendar days for South
Africa, and >180 calendar days for Mozambique (Table 3). All
six agencies had a fast-track review pathway in which applications
were charged a higher fee to be reviewed in a shorter time and a
justification for this may be an unmet medical need.
Data Requirements
For five of the agencies in this study apart from Namibia, the
CPP should be provided either at the time of the application or
before the product is authorized depending on the type of review
(Table 5). In the absence of unredacted reports from reference
agencies, the CPP or evidence of authorization in the country
of origin is used to confirm similarity and approval status of
the product when an abridged review is carried out. Evidence
of compliance with GMP for both the active pharmaceutical
ingredient and finished pharmaceutical product manufacturer,
product samples, copies of the labeling and a full dossier
(modules 1–5) were required for all review types byMozambique,
Namibia, South Africa, and Zimbabwe. Tanzania required full
data for modules 1–5 for a full review and full data for module 3
as well as summaries of modules 4 and 5 for an abridged review.
Zambia required full data for modules 1–5 for a full review
and only summaries of modules 3, 4, and 5 for verification and
abridged reviews.
A detailed assessment of the data was carried out and the
relevant assessment reports prepared. Benefit-risk assessments
were performed during verification and abridged review, taking-
into-account differences in medical culture/practice, ethnic
factors, national disease patterns, and unmet medical needs. All
six agencies participated in the WHO collaborative registration
procedure through which access to reports for prequalified
products is given. As members of the ZaZiBoNa collaborative
procedure, all six agencies had access to reports assessed by this
initiative. South Africa and Zambia accessed internal assessment
reports from their reference agencies. All six agencies made
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TABLE 6 | Comparison of targets for key milestones in the full (type 3) review process -(calendar days).
Target Mozambique Namibia South Africa Tanzania Zambia Zimbabwe
Receipt and validation (A – B) 15 42 18 20 20 90
Queuing (B – C) 180–365 >365 No target 60 180 90
Primary scientific Assessment (C – D) No target No target No target 14 No target 60
Questions to applicant (Clock stop) (D – E) 60 90 42 180 120 60
Review by Expert Committee (G – H) N/A No target No target 1 1–3 1
Approval procedure (Admin) >180 < 30 14 <30 <30 60
Overall approval time (A – I) 365 (excl.
applicant time)









N/A, No expert Committee.
use of publicly available reports such as European Public
Assessment Reports (EPARs) during the review process. The
primary scientific assessment in all six agencies was conducted
by internal staff, although South Africa and Tanzania also made
use of external reviewers.
Part III—Targets for Key Milestones in the
Review Process
The review process and key milestones for the six agencies were
reported in Article 1 (10). The targets for the key milestones
are discussed in this Article. Targets should be set for each
milestone and the overall process in line with good review
practices. Figure 3 is a standardized process map for the review
and approval of medicines with a simplified representation of the
key milestones that are typically recorded and monitored in the
review of applications in a mature regulatory system.
Receipt and Validation
The target for this milestone was 15 calendar days for
Mozambique, 18 calendar days for South Africa, 20 calendar days
for Tanzania and Zambia, 42 calendar days for Namibia, and 90
calendar days for Zimbabwe (Table 6).
Queue Time
Queue time is the time between the completion of
validation/acceptance for review of an application and the
start of the scientific assessment. Namibia had the longest
target queue time of over 365 calendar days followed by the
Mozambique at 180–365 calendar days, Zambia at 180 calendar
days, Zimbabwe at 90 calendar days, and Tanzania had the
shortest target time of 60 calendar days. South Africa reported
no target for the queue time (Table 6).
Primary Scientific Assessment
Tanzania had a target of 14 calendar days for the scientific
assessment (including peer review) while Zimbabwe had a target
of 60 calendar days for the same. Tanzania was able to achieve the
timeline through use of retreats away from the office that allowed
reviewers to focus on review of applications for registration
without any distractions. In addition, the application was split
between a quality reviewer and a bioequivalence reviewer.
Mozambique and South Africa did not report targets for the
scientific assessment even though the milestone was recorded.
Namibia and Zambia did not have a target for primary scientific
assessment and neither did they record the start of this milestone.
Questions to Applicants
This time is also referred to as “clock stop” or company time,
when the assessment is paused and the applicant given an
opportunity to respond to queries. The target for questions to
applicants (clock stop) after each review cycle was 42 calendar
days for South Africa, 60 calendar days for Mozambique and
Zimbabwe, 90 calendar days for Namibia, 120 calendar days for
Zambia, and 180 calendar days for Tanzania.
Review by Expert Committee
In four of the countries, the expert committee made decisions
on the registration or refusal of products. This was done after
first and peer review of applications for registration by internal
reviewers and circulation of reports to members of the expert
committee some days or weeks in advance of the meeting. In one
of the countries, the expert committee was used in an advisory
capacity. The value of the expert committee was that it was made
up of external members with wide and varying expertise who
provided an independent review of the products in addition to
the review conducted by internal reviewers before making the
decision on registration of products. Namibia and South Africa
had no target time for their committee (Council) procedure
while for Tanzania and Zimbabwe the target was 1 day and for
Zambia 1–3 days (Table 6). The expert committees for Namibia,
Tanzania, and Zambia met once a quarter, while the committees
for South Africa and Zimbabwe met once every month.
Authorisation Procedure
The target for this step was 14 calendar days for South Africa,
and <30 calendar days for Namibia, Tanzania, and Zambia.
The applicant was not informed of a positive opinion before
authorization for these agencies. The target for the authorization
procedure was 60 calendar days for Zimbabwe and this was
because the applicant was first informed of a positive opinion
and given an opportunity to respond before authorization. The
authorization procedure took more than 180 calendar days for
Mozambique and the applicant was not informed of a positive
opinion before authorization.
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FIGURE 3 | Standardized review process map for regulatory agencies. The map represents the review and authorization of a product that goes to approval after one
review cycle. It should be noted that in some countries milestone G (committee procedure) may come before milestone D (questions to the applicant).
DISCUSSION
The aim of this article was to compare the review models, target
timelines and metrics of the six countries in the SADC region
that are active members of the ZaZiBoNa collaborative medicines
registration initiative. In terms of numbers of applications
received, the countries with larger populations and those with
the lowest fees receive the highest number of applications. This
study also confirmed the findings reported by previous studies
(1, 11), mainly that the number of new active substances launched
in LMIC is very low compared with high income countries,
demonstrated by some countries having received no applications
for registration of NASs in the last 2 years. Policies promoting
generic prescribing that are implemented by these countries (12)
as well as the lack of affordability by the population may also
be contributing to the high number of applications for generics
received compared to NASs. The resultant effect is the lack of
development of capacity to assess new active substances / new
chemical entities in these countries. Thus, such countries have to
make a deliberate effort to build capacity. Generally, the number
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of products approved declined in 2020 for the majority of the
countries and this could be due to disruptions to work streams,
because of the Covid 19 pandemic.
The six countries studied are practicing reliance by using
the verification and abridged review models for assessment of
applications for registration. This should result in improved
access to life-saving medicines for patients. A great opportunity
identified from this study under review models is for countries
in the region to begin to rely on each other’s decisions for
products assessed using the national procedure. The findings of
this study will aid countries in better understanding the review
processes of the other countries facilitating trust, reliance and
in the future, mutual recognition of regulatory decisions. The
targets set by the countries for the different review models
vary, however this presents another opportunity for countries to
standardize and argue for resources available to other countries
in the region.
Five of the six countries require the WHO certificate of
pharmaceutical product (CPP) at some stage in the review
process confirming findings in the literature that this is
still a requirement for emerging economies (13). Countries
should review the need for the CPP where there is capacity
to conduct a full review as this can affect registration and
supply of medicines by applicants. Key milestones reported
by the six countries are similar and in line with international
best practice. The countries that set targets inclusive of the
applicant’s time should also have targets for agency time only
to facilitate measurement and comparison of performance.
Protracted timelines are undesirable as they affect applicants’
ability to plan or launch new medicines onto the market. In
addition to guidelines, the availability of information in the
public domain on models of review employed, review processes,
timelines for review and approval of medicines, expert committee
meeting dates and status of pending products will improve the
support for existing applicants and attract new applications,
resulting in a growth in the number of products approved on
the market.
Recommendations
As a result of this study, the following recommendation should be
considered by the six agencies taking part in this study and others
in the region.
1. ZaZiBoNa as a reference agency: All agencies participating
in the ZaZiBoNa collaborativemedicines registration initiative
should consider formally recognizing ZaZiBoNa as a reference
agency under the verification and abridged review models.
2. Timelines and targets: In order to benchmark the regulatory
review process, agencies should consider documenting the
key milestones and publishing the relevant timelines. Ideally,
targets should be established for all the key milestones in order
to support the monitoring and measuring of performance.
3. Publication of data: Agencies should consider publishing
the review models that they use for assessment, including
the procedure criteria, recognized reference authorities
and timelines. Agencies without procedural guidelines and
assessment templates should consider developing them.
4. Capacity building: Agencies should consider building
capacity to enable full review of new chemical entities that are
received and not approved by a reference agency.
5. Performance measurement: Countries that currently set
targets inclusive of the applicant’s time should also have targets
for agency time only to facilitate performance measurement.
CONCLUSIONS
Overall, this study identified the strengths of the countries as
well as opportunities for improvement and alignment. This will
enhance the countries’ individual systems, enabling them to
efficiently support the ZaZiBoNa initiative.
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